Our Board of Directors
- Paul LaViolette
- Andrea Biffi
- Jane H. Hsiao, PhD, MBA
- William N. Kelley, MD
- Aftab R. Kherani, MD
- David B. Milne
- Richard C. Pfenniger, Jr
- Todd M. Pope
- William Starling
Chairman of the Board
Mr. LaViolette brings nearly 30 years of experience in global medical technology marketing and general management to the TransEnterix board.
Before joining SV Life Sciences, an international life-science venture capital firm, in 2009, Mr. LaViolette served as chief operating officer for Boston Scientific Corp., an $8-billion medical device leader. During his 15 years with Boston Scientific, he held the positions of group president, president-cardiology and president-international as the company multiplied its revenues over 20 times. He integrated dozens of acquisitions and led extensive product development, operations and worldwide commercial organizations.
Before joining Boston Scientific, Mr. LaViolette held marketing and general management positions at CR Bard and Kendall (Tyco). In addition to his position on the TransEnterix board, LaViolette serves on the boards of Cameron Health, CardioFocus, Conceptus, DC Devices, Direct Flow Medical, DJO Global, Thoratec, ValenTx and Medical Device Manufacturers Association (MDMA). He previously has served on the boards of Urologix, Percutaneous Valve Technologies and Advamed.
Mr. LaViolette received his bachelor’s of arts degree in psychology from Fairfield University and holds a master’s degree in business administration from Boston College.
Andrea Biffi was elected to the Board of Directors in September 2015. Mr. Biffi is currently the Chief Executive Officer, and a member of the Board of Directors, of SOFAR S.p.A., a position he has held since June 2015. Mr.Biffi has worked for SOFAR, or companies owned by SOFAR, since January 2008.
Prior to becoming Chief Executive Officer, Mr. Biffi was General Manager, and a member of the Board of Directors, of SOFAR from November 2012 until June 2015; prior thereto he was CEO and President of SOFAR SWISS S.A. from February 2013 to November 2013; and prior thereto he was General Manager of SOVETA BALTICA UAB, a Lithuanian subsidiary of SOFAR from January 2008 until November 2013.
Dr. Hsiao brings to the board technical and leadership expertise in pharmaceutical, medical device and life science industries. Currently, she serves as Chief Technical Officer at OPKO Health Inc., a multi-national pharmaceutical and diagnostics company, and serves as its board Vice Chairman. Prior to the merger with TransEnterix, Dr. Hsiao served as Chairman of the Board of SafeSitch Medical, Inc. She also serves as Chairman of the Board and interim CEO of Non-Invasive Monitoring Systems Inc., a medical device developer. Dr. Hsiao also currently serves on the board of Neovasc, Inc., a company developing and marketing medical specialties in vascular devices. Previously, Dr. Hsiao held a number of senior management positions at IVAX Corp., including vice chairman-technical affairs, chief technical officer and chief regulatory officer. Teva Pharmaceutical Industries, one of the top 10 pharma companies in the world, acquired IVAX Corp. in 2006.
Dr. Kelley is currently Professor of Medicine at the School of Medicine of the University of Pennsylvania. From 1989 to 2000, Dr. Kelley served as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. In the national leadership arena, Dr. Kelley has served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Within the past five years, Dr. Kelley served on the board of directors of Merck & Co. Inc., Beckman Coulter, Inc., Advanced Biosurfaces, Inc. and Polymedix, Inc. He is also a director of GenVec, Inc., a position he has held since June 2002.
Aftab Kherani serves as a principal of Aisling Capital. Previously, he was an engagement manager at McKinsey & Company, where he was a member of the pharmaceutical, medical product and private equity practices.
Prior to joining McKinsey, Dr. Kherani was a chief resident in surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure and arrhythmia in the laboratory of Dr. Mehmet Oz at Columbia University, College of Physicians & Surgeons. While at Columbia, he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.
Mr. Milne served as a Managing Partner at SV Healthcare Investors, a leading international life sciences venture capital firm, from 2005 to 2017. Prior to joining SV he had 20 years of operating experience in the healthcare industry having worked at several leading public and private medical technology companies. From 1999 until joining SVLS in 2005, he held the position of Vice President of Corporate Business Development at Boston Scientific and was responsible for over 50 transactions totaling nearly $2 billion in acquisitions, equity investments and development partnerships.
Previously Mr. Milne worked at Scimed Life Systems, Becton Dickinson and Parker Laboratories. Mr. Milne currently sits on the boards of Entellus Medical, a publicly traded company, and Spinal Kinetics, a privately-held company. He has been on the board of directors of an additional 14 public and private companies. He holds an MBA in Marketing/Finance from New York University and a BS in Biology from Rutgers University.
Richard C. Pfenniger, Jr. brings to the board experience as chief executive officer, chief operating officer and general counsel. Most recently, Mr. Pfenniger served as interim CEO of IntegraMed America Inc., a privately held company offering products and services to providers and consumers in niche medical sectors. Previously, he served as CEO and president of Continucare Corp., a provider of primary care physicians, and served as its board chairman.
Additionally, Mr. Pfenniger served as CEO and vice chairman of Whitman Education Group Inc., a proprietary provider of career-oriented post-secondary education. He also has served as COO, senior vice president-legal affairs and general counsel for IVAX Corp., a manufacturer and distributor of generic pharmaceutical products later acquired by Teva Pharmaceutical Industries.
Mr. Pfenniger serves as a director of GP Strategies Inc., a corporate education and training company; OPKO Health Inc., a multi-national pharmaceutical and diagnostics company; IntegraMed and prior to the merger with TransEnterix, served on the SafeSitch Medical Inc. board since 2005.
As president and chief executive officer, Todd M. Pope sets the company’s strategic vision and oversees its organic growth. Mr. Pope has spent more than 25 years working in key leadership positions within the medical-device industry.
Prior to joining TransEnterix, Mr. Pope served as worldwide president of Cordis, a multi-billion-dollar division within Johnson & Johnson’s medical-device sector. He previously held a number of leadership positions within Johnson & Johnson and Boston Scientific.
Mr. Pope has a special passion for managing emerging start-ups that have disruptive technologies with the potential to change the landscape of current standard of care.
William N. Starling is managing director of Synergy Life Science Partners, and chief executive officer of Synecor, a business generator of new life–science companies. He has raised more than $300 million in capital for companies he co–founded – the combined revenues of which now reach nearly $3 billion annually. As CEO of Synecor, Mr. Starling co–founded TransEnterix as well as BaroSense, Bioerodible Vascular Solutions (acquired by Guidant/Abbott in April 2004), InnerPulse and Interventional Autonomics Corp. Mr. Starling serves as board chairman of InnerPulse, board chairman of Interventional Autonomics Corp., and as a board member of TransEnterix.
Mr. Starling began his 30–year career in medical technologies at American Edwards Laboratories (now Edwards LifeSciences). There, he was part of the founding management team, served as marketing director for Advanced Cardiovascular Systems Inc. (acquired by Guidant/Abbott) and was co-founder, vice president and board member of Ventritex Inc. (acquired by St. Jude Medical). In addition, Mr. Starling was a co–founder, board chairman, and president and CEO of Cardiac Pathways Corp. (acquired by Boston Scientific Corp.).
A graduate of the University of North Carolina at Chapel Hill, Mr. Starling received an MBA from the University of Southern California.